TY - JOUR AU - Zou, W. AU - Wolchok, J. D. AU - Chen, L. PY - 2016 DA - 2016// TI - PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations JO - Sci Transl Med VL - 8 UR - https://doi.org/10.1126/scitranslmed.aad7118 DO - 10.1126/scitranslmed.aad7118 ID - Zou2016 ER - TY - JOUR AU - Nishino, M. AU - Jagannathan, J. P. AU - Krajewski, K. M. AU - O'Regan, K. AU - Hatabu, H. AU - Shapiro, G. AU - Ramaiya, N. H. PY - 2012 DA - 2012// TI - Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST JO - AJR Am J Roentgenol VL - 198 UR - https://doi.org/10.2214/AJR.11.7483 DO - 10.2214/AJR.11.7483 ID - Nishino2012 ER - TY - JOUR AU - Hoos, A. AU - Parmiani, G. AU - Hege, K. AU - Sznol, M. AU - Loibner, H. AU - Eggermont, A. AU - Urba, W. AU - Blumenstein, B. AU - Sacks, N. AU - Keilholz, U. AU - Nichol, G. PY - 2007 DA - 2007// TI - A clinical development paradigm for cancer vaccines and related biologics JO - J Immunother VL - 30 UR - https://doi.org/10.1097/01.cji.0000211341.88835.ae DO - 10.1097/01.cji.0000211341.88835.ae ID - Hoos2007 ER - TY - JOUR AU - Giacomo, A. M. AU - Danielli, R. AU - Guidoboni, M. AU - Calabro, L. AU - Carlucci, D. AU - Miracco, C. AU - Volterrani, L. AU - Mazzei, M. A. AU - Biagioli, M. AU - Altomonte, M. AU - Maio, M. PY - 2009 DA - 2009// TI - Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-008-0642-y DO - 10.1007/s00262-008-0642-y ID - Giacomo2009 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O'Day, S. AU - Weber, J. S. AU - Hamid, O. AU - Lebbe, C. AU - Maio, M. AU - Binder, M. AU - Bohnsack, O. AU - Nichol, G. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER - TY - STD TI - Kazandjian DG, Blumenthal GM, Khozin S, Suzman DL, Keegan P, Pazdur R. Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial. J Clin Oncol. 2016;34(suppl; abstr 3000). ID - ref6 ER - TY - JOUR AU - Chiou, V. L. AU - Burotto, M. PY - 2015 DA - 2015// TI - Pseudoprogression and immune-related response in solid tumors JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.6870 DO - 10.1200/JCO.2015.61.6870 ID - Chiou2015 ER - TY - STD TI - al SJAe. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33:2015. ID - ref8 ER - TY - JOUR AU - Naidoo, J. AU - Page, D. B. AU - Li, B. T. AU - Connell, L. C. AU - Schindler, K. AU - Lacouture, M. E. AU - Postow, M. A. AU - Wolchok, J. D. PY - 2015 DA - 2015// TI - Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies JO - Ann Oncol VL - 26 ID - Naidoo2015 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. AU - Chow, L. Q. AU - Vokes, E. E. AU - Felip, E. AU - Holgado, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crino, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. AU - Antonia, S. AU - Pluzanski, A. AU - Vokes, E. E. AU - Holgado, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced Squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER -